Diagnostic and therapeutics company Enzo Biochem Inc (NYSE:ENZ) disclosed on Monday that it recorded a GAAP net loss was USD10.3m ( USD0.22 GAAP net loss per share) for the fiscal year ended 31 July 2018.
This is a dip in earnings when compared with lower GAAP net loss of USD2.5m (USD0.05 GAAP net loss per share) a year ago.
Total revenues of USD104.7m were generated for the fiscal year ended 31 July 2018, a decline of 3.1% from USD107.8m in the prior year. The decline year over year resulted from lower product royalties from an agreement that expired in April 2018.
Consolidated gross margins of 42% were for the fiscal year ended 31 July 2018, a fall over 45% in the prior year.
EBITDA was a loss of USD9.1m for the fiscal year ended 31 July 2018, down against earnings of USD0.7m a year ago.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development